Inflammatory Diseases
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-16.png)
Naïve, protein-naïve and non-naïve study subjects.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-03.png)
Acute, short-infusion or repeated dosing designs.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-09.png)
General, tissue and cell-specific inflammatory evaluations.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-02.png)
Full clinical chemistry, clinical pathology and clinical toxicology support.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-11.png)
Tissue-specific safety biomarker levels by biosampling, biopsy or microdialysis.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-14.png)
Organ-specific or complete histology and pathology evaluation.
Extensive inflammation models in cynomolgus and marmosets with functional and clinical assessments:
- Dermal inflammation: DI
- Irritable bowel diseases: IBD
- Multiple sclerosis: MS
- Respiratory/asthma/COPD: RAC
- Sepsis/ endotoxemia: ET
- Wound healing: WH
Comprehensive inflammation biomarkers assays:
- Standard and expanded multiplexed cytokine assays
- Immune markers (comprehensive CD markers panels by flow cytometry)
- Acute phase proteins assays (CRP and SAA)
- Cellular lipid markers assays